Posted by Michael Wonder on 02 Aug 2022
Delay of Evrysdi reimbursement review denies SMA patients' right to drug choice
2 August 2022 - The Government has been dragging its feet to review insurance benefits for Roche's new spinal muscular atrophy oral drug Evrysdi (risdiplam) for over a year because it wants to review it together with expanded insurance coverage for the existing spinal muscular atrophy drug Spinraza (nusinersen sodium), sources said.
The intentional delay of the drug review might infringe upon spinal muscular atrophy patients' right to choose a medicine, they noted.
